2/7/2013

Biogen Idec agreed to pay Elan $3.25 billion plus future royalties to acquire all rights to multiple sclerosis drug Tysabri, or natalizumab. Tysabri was jointly developed by Biogen and Elan. The deal will strengthen Biogen's presence in the multiple sclerosis drug market as it awaits the FDA's decision on another MS drug, Tecfidera, or dimethyl fumarate.

Related Summaries